revenu ep ahead estim full year ep guidanc rais
humira sale guidanc unchang ou trend appear weaker expect
part neg fx expect favor easier
ep estim consensu
ep guidanc increas prior ep guidanc set
vs last publish rais ep forecast
reflect beat futur estim review
sale estim
consensu drug beat estim includ humira imbruvica
androgel lupron kaletra creon combin
forecast product forecast includ mavyret sevofluoran duodopa
synthroid combin estim specif product sale
guidanc full year unchang earn call humira guidanc
 growth ou cer guidanc call humira sale ou
sale vs last publish skyrizi sale guidanc set
vs last publish
gpm estim
estim sg forecast net interest
expens estim pre-tax margin
estim tax rate line share count
estim updat guidanc includ gpm approach vs prior
oper margin vs prior
event expect includ imbruvica gazyva full data cll
upadacitinib /eu approv ra pdufa skyrizi
risankizumab eu approv psoriasi posit chmp venclexta gazyva
approv cll orilissa file uterin fibroid complet list
event shown follow page
pleas see page report import disclosur
provid long-term guidanc expect humira appear
solid foot forese futur competit posit
hepat segment oncolog compani pipelin promis
agent opportun upward revis sever front stock
attract valu versu group overal attribut argu purchas
upadacitinib approv ra
humira sale trend particularli
orilissa uptak endometriosi uterin
humira sale
humira biosimilar eros less
especi oncolog immunolog
 bolster long-term visibl
humira erod quickli
expect eu and/or launch
oncolog immunolog product
global biopharmaceut compani product use treat rheumatoid
arthriti psoriasi crohn ulcer coliti hcv hematolog tumor among other
humira ra crohn domin product repres total sale
profit also pipelin compound indic phase ii
phase develop
cowen compani
chg total good profit margin profit gross gross profit profit gross gross profit oper foreign exchang gain expens incom expens incom share cowen
cowen compani
reportedour estimatedifferenceproduct exceed cowen
cowen compani
cowen compani
time frameev data gbmemplic w/bmi phase interim data mmimbruvicaphas allianc data cll selen data r/r fl/mzl late shine data mcl late risankizumab initi phase data r/r sclc w/nivo /- ipiphas meru data sclc mainten late jaki phase data select- ii data axial spainiti phase axial spa gcavencelxta w/rhhbi phase data amliniti phase mm gazyva w/rhhbi full ph data cll posit top-lin oct vela data non-sq nsclc w/bmi eu approv r/r mm w/poma dex imbruvica gazyvaeu approv unfit cll illumin eu approv wmorilissafil uterin fibroid risankizumab eu approv psoriasi posit chmp jaki approv ra pdufa gazyvaapprov unfit cll cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ heavi depend humira sale ep success pipelin
product notabl hepat portfolio success independ compani
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock novarti adr roch hold ltd adr secur
cowen compani llc act underwrit announc initi public offer elanco anim health incorpor subsidiari co
cowen compani llc act financi advisor inc connect acquisit roch hold ag announc februari
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
